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A B S T R A C T
An important unknown during the coronavirus disease-2019 (COVID-19) pandemic has been the
infection fatality rate (IFR). This differs from the case fatality rate (CFR) as an estimate of the number of
deaths and as a proportion of the total number of cases, including those who are mild and asymptomatic.
While the CFR is extremely valuable for experts, IFR is increasingly being called for by policy makers and
the lay public as an estimate of the overall mortality from COVID-19.
Methods: Pubmed, Medline, SSRN, and Medrxiv were searched using a set of terms and Boolean operators
on 25/04/2020 and re-searched on 14/05/2020, 21/05/2020 and 16/06/2020. Articles were screened for
inclusion by both authors. Meta-analysis was performed in Stata 15.1 by using the metan command,
based on IFR and confidence intervals extracted from each study. Google/Google Scholar was used to
assess the grey literature relating to government reports.
Results: After exclusions, there were 24 estimates of IFR included in the final meta-analysis, from a wide
range of countries, published between February and June 2020.
The meta-analysis demonstrated a point estimate of IFR of 0.68% (0.53%–0.82%) with high heterogeneity
(p < 0.001).
Conclusion: Based on a systematic review and meta-analysis of published evidence on COVID-19 until July
2020, the IFR of the disease across populations is 0.68% (0.53%–0.82%). However, due to very high
heterogeneity in the meta-analysis, it is difficult to know if this represents a completely unbiased point
estimate. It is likely that, due to age and perhaps underlying comorbidities in the population, different
places will experience different IFRs due to the disease. Given issues with mortality recording, it is also
likely that this represents an underestimate of the true IFR figure. More research looking at age-stratified
IFR is urgently needed to inform policymaking on this front.
© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The year 2020 saw the emergence of a global pandemic, coronavirus
disease-2019(COVID-19),causedbytheSARS-CoV-2virus,whichbegan
in China and has since spread across the world. One of the most
challenging questions to answer during the COVID-19 pandemic has
been regarding the true infection fatality rate (IFR) of the disease. While
case fatality rates (CFR) are eminentlycalculable fromvarious published
data sources (Kahathuduwa et al., 2020) – CFR being the number of
deaths dividedbythenumberof confirmedcases– it is farmoredifficult
toextrapolatetotheproportionofall infectedindividualswhohavedied
due to the infection because those who have very mild, atypical or
asymptomatic disease are frequently left undetected and therefore
omitted from fatality rate calculations (Rinaldi and Paradisi, 2020).
Given the issues with obtaining accurate estimates, it is not unexpected
that there are wide disparities in the published estimates of case
numbers. This is an issue for several reasons, most importantly in that
policy is dependent on modelling, and modelling is dependent on
assumptions. If we do not have a robust estimate of IFR, it is challenging
to make predictions about the true impact of COVID-19 in any given
susceptiblepopulation,whichmaystymiepolicydevelopmentandmay
have serious consequences for decision-making into the future. While
CFR is a more commonly used statistic, and is very widely understood
among experts, IFR provides important context for policymakers that is
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G. Meyerowitz-Katz and L. Merone International Journal of Infectious Diseases 101 (2020) 138–148terested in the total burden in the population rather than the biased
stimates given from testing only the acutely unwell patients.
This is particularly important when considering the reopening
f countries post ‘lockdown’. Depending on the severity of the
isease, it may be reasonable to reopen services such as schools,
ars, and clubs, at different timings. Another salient point is the
xpected burden of disease in younger age groups — while there
re likely long-term impacts other than death, it will be important
or future planning to know how many people in various age
roups are likely to die if the infection becomes widespread across
ocieties. Age-stratified estimates are also important as it may give
ountries some way to predict the number of deaths expected
iven their demographic breakdown.
There are a number of methods for investigating the IFR in a
opulation. Retrospective modelling studies of influenza, as a
ommon cause of global pandemics, have successfully predicted
he true number of cases and deaths from influenza-like illness
ecords and excess mortality estimates (Wong et al., 2013;
hompson et al., 2009). However, these may not be accurate, in
art due to the general difficulty in attributing influenza cases to
ubsequent mortality, meaning that CFRs may both overestimate
nd equally underestimate the true number of deaths due to the
isease in a population (Spychalski et al., 2020).
The standard test for COVID-19 involves polymerase chain
eaction (PCR) testing of nasopharyngeal swabs from patients
uspected of having contracted the virus. This can produce some
alse negatives (Anon, 2020a), with one study demonstrating
lmost a quarter of patients experiencing a positive result
ollowing up to two previous false negatives (Xiao et al., 2020).
he sensitivity of PCR is believed to be around 70%, which may lead
o the underdiagnosis of COVID-19 (Fernández-Barat et al., 2020).
CR is also limited in that it cannot test for previous infection.
erology testing is more invasive, requiring a blood sample.
owever, it can determine whether there has been previous
nfection and can be performed rapidly at the point of care (PoC).
erology PoC testing cannot determine if a person is infectious or if
nfection is recent and there is a risk of misinterpretation of results
Winter and Hegde, 2020). Generally, serology testing is more
sensitive and specific than PCR, but will still likely overestimate
prevalence when few people have been infected with COVID-19
and underestimate in populations with more infections (Lisboa
Bastos et al., 2020). Additionally, there has been great variation
noted in the sensitivity, the ability of the test to detect truly
positive cases, of COVID-19 serology tests (Ghaffari et al., 2020).
Serological tests are reliant on seroconversion, which in COVID-19
occurs several days after the viral load has peaked, meaning
serology is less effective in the earlier stages of the disease
(Ghaffari et al., 2020). Some studies suggest that there are those
who do not seroconvert at all (Staines et al., 2020). The lack of
reliable testing may be problematic for estimating CFRs and IFRs.
Given the emergence of COVID-19 as a global pandemic, it is
somewhat unlikely that these issues are entirely the same for the newer
disease, but there are likely similarities between the two. Some analysis
in mainstream mediapublicationsandpre-printshas impliedthatthere
is a large burden of deaths that remains unattributed to COVID-19.
Similarly, serological surveys have demonstrated that there is a large
proportion of cases that have not been captured in the case numbers
reported in the US, Europe and potentially worldwide (Bendavid et al.,
2020; Erikstrup et al., 2020; Simon, 2020).
This paper presents a systematic effort to collate and aggregate
these disparate estimates of IFR using an easily replicable method.
While any meta-analysis is only as reliable as the quality of
included studies, this will at least put a realistic estimate to the IFR
given current published evidence.
Methods
This study used a simple systematic review protocol. PubMed,
MedLine, and Medrxiv were searched on the 25/04/2020 using the
terms and Boolean operators: (infection fatality rate OR ifr OR
seroprevalence) AND (COVID-19 OR SARS-CoV-2). This search was
repeated on 14/05/2020, 25/05/2020 and 16/06/2020. The
pre-print server SSRN was also searched on 25/05/2020; however,
as it does not allow this format, the Boolean operators and brackets
were removed. While Medrxiv and SSRN would usually be
excluded from systematic review, given that the papers included139
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Table 1
Results of the systematic review of published research data on COVID-19 infection fatality rates.
Study Location Study period Method and sample size Results
Bassett (2020) New York (NYC)
(USA), Madrid,
Lombardy
Until 22nd April 2020
(commence date not
provided)
Utilised R0 of 2.4 to calculate a predicted infection
rate of 81% (UK and USA).
Over the 3 regions, the IFR (using predicted total
infection rate of 81%) was calculated at 0.17%, for
each region specifically, using the same predicted






2 days Serological testing of 3300 local adults and
children. Volunteer sampling. Bootstrap
procedure used for weighted and unweighted
prevalence estimates.
Crude prevalence rate 1.5% (95%CI 1.1%–2.0%),
unweighted population prevalence 1.2%
(bootstrap 95%CI 0.7%–1.8%), weighted
population prevalence 2.8% (95%CI 1.3%–4.7%).
Number of infections estimated to be greater than




Czech Republic Unspecified start date,
concluded 1st May 2020
Tested 26,549 people for antibodies (serology). Uncovered 107 new cases.
Government of
Denmark
Denmark Reported on 20th May 2020 Tested 1,071 people out of a total sample of 2600
for antibodies.
An estimated 1.1% seroprevalence, with a






England, UK As of 24th May 2020 Serology samples randomly gathered from 885
people up until 24/05/2020





Indiana, USA 7 days Tested >4600 using viral PCR and serum for
antibodies; 3600 randomly selected individuals
and 900 volunteers.
1.7% tested positive for COVID-19 on PCR plus an
additional 1.1% who tested positive for antibodies.




Finland Week 22 Random weekly sampling of the Finnish
population, week 22 included 178 samples
5 positives from 178 lead to a 2.81% positive rate,
ranging from 1.21% to 6.41%.
Government of
Slovenia
Slovenia Not specified 1367 swabs and 1367 blood samples collected
from a representative sample of the population.






27/04/2020–11/05/2020 60,983 participants invited, of which so far 37,992
(62.3%) have responded
5% positive on serology, with death rates varying







1200 weekly samples. Initial analysis was
reported from 1104 samples.
7.3% tested positive on serology in Stockholm
county. Official government report estimates IFR




Brazil From 14th May to 21st May
2020
46,011 attempts lead to a total of 25,025 samples
across every region of Brazil.
An overall seroprevalence of 1.39%, with the
authors reporting a calculated IFR of 1%, although
it was impossible to ascertain whether this
accounted for right censoring.
Herzog et al.
(2020)
Belgium Two time periods in April,
with the estimate used in
this paper from the 20–26
of April 2020
Total of 7307 samples from locations around
Belgium
193 out of 3397 samples tested positive, with a
weighted overall seroprevalence of 3.1%.
Combined with death estimates, this produced an







16 days A total of 51 cases diagnosed between 24/09/2020
and 09/02/2020. Data collected from government
websites or media quoting government
announcements.
Mean time from illness onset to death was 20.2
days. Estimated incidence in China on 24/01/2020







Used data from 01/01/
2015–28/03/2020
Utilised data from the Italian Institute of
Statistics. Compared death rates during the
COVID-19 pandemic to previous death rates by
age and region.
Clear increase in deaths was noted for early 2020.
IFR increases with age. Range 0.02% (40-49 years








3 days A total of 565 individuals screened for symptoms
and tested for COVID-19 (PCR).
A total of 8 passengers tested PCR positive for
COVID-19 (1.4%). Estimated ascertainment rate of








Utilised 5-year death data
until April 2020
Collected data from the Italian Institute of
Statistics. The total population of the included
municipalities was 50563. Bayesian model used
to estimate IFR.
Deaths between February and April 2020 were 5-
fold the 2015–2019 average (341 versus 70). IFR
1.29% (95%CI 0.89–2.01), increasing to 4.25% for
those >60 years old (95%CI 3.01%–6.39%)
Roques et al.
(2020)
France 54 days Obtained data on positive cases and deaths from
Johns Hopkins University Centre for Systems
Science and Engineering and data on tests
performed from Santé Publique France, deaths
from nursing homes were added to the official
count.
Calculated IFR 0.5% (95%CI 0.3–0.8), when nursing
home residents were adjusted for estimated IFR
0.8% (95%CI 0.45–1.25). Estimated ratio between






9 days Cross-sectional Seroprevalence study of 15,101
adults. Used IgG immunoassay approved for
COVID-19
12.5% of specimens were reactive. Cumulative
incidence was noted to be higher in Hispanic







14–17 days A total of 3711 passengers and staff were tested
(PCR) whilst in quarantine. Utilised data from the
World Health Organisation situational reports.
There were 619 confirmed cases (17%), 318 of
whom were asymptomatic (51%). Corrected CFR
was 2.6% (95%CI 0.89%–6.7%). Corrected IFR was
1.3% (95%CI 0.38%–3.6%). CFR increased with age
(3.6% for those aged 60–69 years, 95%CI 3.2–4.0)
and 14.8% for those >80 years, 95%CI 13.0–16.7).
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G. Meyerowitz-Katz and L. Merone International Journal of Infectious Diseases 101 (2020) 138–148re not peer-reviewed, during the pandemic it has been an
mportant source of information and contains many of the most
ecent estimates for epidemiological information about COVID-19.
nclusion criteria for the studies were:
- Regarding COVID-19/SARS-CoV-2 (i.e. not SARS-CoV-1 extrap-
olations).
- Presented an estimated population IFR (or allowed the calcula-
tion of such from publicly available data).
Titles and abstracts were screened for eligibility and discarded
f they did not meet the inclusion criteria. GMK then conducted a
imple Google and Google Scholar search using the same terms to
ssess the grey literature, in particular published estimates from
overnment agencies that may not appear on formal academic
atabases. LM assessed the articles to ensure congruence. If these
et the inclusion criteria, they were included in the systematic
eview and meta-analysis. Similarly, Twitter searches were
erformed using similar search terms to assess the evidence
vailable on social media. Estimates for IFR and the confidence
nterval were extracted for each study.
All analysis and data transformation were performed in Stata
5.1. The meta-analysis was performed using the metan command
or continuous estimates, with IFR and the lower/upper bounds of
he confidence interval as the variables entered. This model used
he DerSimonian and Laird random-effects method. The metan
ommand in Stata automatically generates an I2 statistic that was
Sensitivity analyses were performed stratifying the results into
the type of study – serological vs non – by country, and by the
month of calculation.
The metabias and metafunnel commands were used to examine
publication bias in the included research, with Egger’s test used for
the metabias estimation. It was challenging to formally rate the
risk of bias of the included modelling studies, as there was very
significant heterogeneity in methodology and implementation,
with the result that the risk of bias in these studies was considered
to be high across all included research. Serological surveys were
rated using the risk of bias in the prevalence tool with a resulting
estimate in line with Cochrane GRADE criteria of low, moderate or
high (Hoy et al., 2012). This tool asks a series of 10 questions about
the sampling and data collection of prevalence studies, with a final
rating based on the previous questions. Each question is answered
yes/no, with a lack of information presumed to be no/unclear. A
separate sensitivity analysis was conducted using only serological
survey results stratified by the risk of bias.
Because of a recent surge in the number of serological surveys
being published, these were included in the infection fatality
estimate despite not formally calculating an IFR in the study text
itself. Regional death rates were taken from the John Hopkins
University CSSE dashboard (Dong et al., 2020) 10 days after the
serosurvey completion where no IFR was calculated to account for
right-censoring of these estimates (Giorgi Rossi et al., 2020), and
used to estimate the IFR given the population.
All code and data files are available (in. do and. csv format) upon
able 1 (Continued)








Data available up to 7th
May 2020
Modelling analysis of COVID-19 transmission in
France. This included 95,210 hospitalisations and
719 infections from the Diamond Princess Cruise
Ship.
3.6% of infected individuals were hospitalised
(95% CI 2.1%-5.6%) and this percentage increased
with age and gender (0.2% females <20 years;
45.9% males >80 years). IFR 0.7% (95%CI 0.4%–




Iran 1 month Cluster randomised sampling utilised to obtain
551 rapid antibody tests for COVID-19
22% antibody seropositivity. 18% (65 subjects)




commenced on 15 April
2020
Recruited voluntary residents of Luxembourg.
Performed PCR for COVID-19 in 1842 participants
and serology testing in 1820 participants.
Low prevalence of carriers (0.3%). Seroprevalence
of IgA was 11%, and 2% for IgG. Of 1842 PCR tests,
only 6 were inconclusive (0.3%). Time prevalence
of COVID-19 was 0.32 (95%CI 0.02–0.63).
Streeck et al.
(2020)
Germany 7 days A sero-epidemiological CGP and GEP-compliant
study in a town exposed to a super-spreading
event. Utilised a questionnaire and PCR/serology
testing 6 weeks after outbreak. A sample of 919
individuals had evaluable infection status.
Infection rate or 15.5% (95% CI 12.3%–19.0%); this
was 5-fold reported cases in the community
(3.1%). Estimated IFR 0.36% (95% CI 0.29–0.45).
Stringhini et al.
(2020a)
Switzerland Three serosurveys over
several time periods, with
the final results reported on
June 2nd
Longitudinal serological survey, with an
accompanying paper estimating infection fatality
rate as well.
Infection-fatality rate estimated by authors was




Beijing, China 21 days 262 cases retrospectively enrolled and
characteristics compared between severe, mild
and asymptomatic patients using Mann–Whitney
U tests and Wilcoxon tests.
Five patients died and 46 were classified as
severe. IFR in Beijing was lower than nationally;







56 days Age-stratified CFR estimates on 1334 cases
outside mainland China. Used prevalence data
from PCR-confirmed cases in international
residents repatriated from China to determine
IFR.
Mean time from illness onset to death 17.8 days
(95%CI 16.9–19.2). CFR in China 1.38% (95%CI
1.23–1.53), increasing with age to 6.8% in those
aged >65 years (95%CI 5.7%–7.2%) and 13.4% in




Italy 32 days Collected data from Italy’s Civil Protection Agency
from each of Italy’s 20 regions.
Estimated an IFR of 1.1% (95%CI 0.2%–2.1%) and a
CFR of 12.7%.sed to investigate heterogeneity. Histograms were visually
nspected to ensure that there was no significant positive or
egative skew to the results that would invalidate this methodol-
gy. For the studies where no confidence interval was provided,
ne was calculated.
A PRISMA flow diagram of the search methods.14
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study. These came from a variety of sources, with some appearing
from blog posts, others posted on Twitter, and some government
documents being found through Google. There were no duplicates
specifically, however, two pre-prints had been published and so
appeared in slightly different forms in both databases. In this case,
the published study was used rather than the pre-print. Results are
collated in Table 1.
Studies were excluded for a variety of reasons. Some studies only
looked at COVID-19 incidence, rather than the prevalence of antibodies,
andwerethusconsideredpotentiallyunreliableaspopulationestimates
(Gudbjartsson et al., 2020). The most common reason for exclusion was
selection bias — many studies only looked at targeted populations in
their seroprevalence data, and thus could not be used as population
estimators of IFR (Erikstrup et al., 2020; Doi et al., 2020; Takita et al.,
2020; Jerkovic et al., 2020; Valenti et al., 2020; Garcia-Basteiro et al.,
2020; Fontanet et al., 2020; Thompson et al., 2020; Ed Slot and Reusken,
2020). For some data, it was difficult to determine the numerator (i.e.
number of deaths) associated with the seroprevalence estimate or the
denominator (i.e. population) was not well defined and thus we did not
calculate an IFR (Silveira et al., 2020; Bryan et al., 2020). One study
explicitly warned against using its data to obtain an IFR (Sood et al.,
2020). Another studycalculated an IFR, but did not allow foran estimate
of confidence bounds and thus could not be included in the quantitative
synthesis (Wilson, 2020).
After screening titles and abstracts, 227 studies were removed.
Many of these looked at case fatality estimates or discussed IFR as a
concept and/or a model input, rather than estimate the figure
themselves. Forty papers were assessed for eligibility for inclusion
in the study, which resulted in a final 25 to be included in the
qualitative synthesis.
Studies varied widely in design, with 3 entirely modelled
estimates (Nishiura et al., 2020; Jung et al., 2020; Salje et al., 2020),
4 observational studies (Bendavid et al., 2020; Verity et al., 2020;
Tian et al., 2020; Russell et al., 2020), 5 pre-prints that were
challenging to otherwise classify (Rinaldi and Paradisi, 2020;
Roques et al., 2020; Villa et al., 2020; Modi et al., 2020a; Streeck
et al., 2020), and a number of serological surveys of varying types
reported by government agencies (Bassett, 2020; Anon, 2020b; IU,
2020; Snoeck et al., 2020; Slovenia RO, 2020; Anon, 2020c; Shakiba
et al., 2020; Statistics OFN, 2020; Hallal et al., 2020; Institut SS,
2020; Folkhälsomyndigheten, 2020a; Anon, 2020e; Stringhini
et al., 2020b). For the purposes of this research, an estimate for
New York City was calculated from official statistics and the
serosurvey; however, this was correlated with a published
estimate (Wilson, 2020) to ensure validity.Figure 1.
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G. Meyerowitz-Katz and L. Merone International Journal of Infectious Diseases 101 (2020) 138–148The main result from the random effects meta-analysis is
resented in Figure 1. Overall, the aggregated estimate across all 24
tudies indicated an IFR of 0.68% (95% CI 0.53%–0.82%), or 68 deaths
er 10,000 infections. Heterogeneity was extremely high, with the
verall I2 exceeding 99% (p < 0.0001) (Figure 2).
The monthly sensitivity analysis from Figure 3 showed that
arlier estimates of IFR were lower, with later estimates showing a
igher figure, although this appears to have stabilised in May.
Analysing by the region of origin did not appear to have a
ubstantial effect on the findings, although there was a slightly
ower estimate seen in Asia. As the Middle East was only
epresented by one study, this region was excluded from the
eta-synthesis by region. Two studies were also excluded as
hey did not present an IFR for a specific region (i.e. Diamond
rincess).
Of note, there was some difference in the estimates of IFR
etween estimates based on serosurveys and those of modelled or
CR-based estimates. The overall estimates from serosurvey
tudies were 0.60% (0.42%–0.77%), although again with very high
eterogeneity, as can be seen in Figure 4.
There were insufficient data in the included research to perform
 meta-analysis of IFR by age. However, qualitatively synthesizing
he data that were presented indicates that the expected IFR below
the age of 60 years is likely to be reduced by a large factor. This is
supported by studies examining the CFR, which were not included
in the quantitative synthesis and studies examining IFR in selected
populations younger than 70 years of age that demonstrate a
strong age-related gradient to the death rate from COVID-19.
Plotting the studies using a funnel plot produced some visual
indication of publication bias, with more high estimates than
would be expected; however, the Egger’s regression was not
significant (p = 0.74).
Risk of bias
As previously noted, all estimates obtained from modelling
studies are considered to be at a high risk of bias due to the
heterogeneity and difficulty in rating these studies for accuracy.
After using the rating ‘risk of bias’ tool for prevalence studies, 6
studies were considered to be at a low risk of bias, 4 studies at a
moderate risk of bias, and the remaining 5 estimates at a high risk
of bias. This is summarized in the table below (full scoring in
Supplementary materials) (Table 2).
In general, the primary reason for down-rating studies was non-
response bias, the lack of representativeness of the population
sample, and a lack of information across all fields. Some reportsFigure 2.
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increased the uncertainty and thus the risk of bias in these
estimates.
The sensitivity analysis by study quality results are given below.
Broadly, study quality was correlated with a higher inferred IFR,
with lower-quality serosurveys reporting higher estimates of
population prevalence than randomly sampled population-wide
prevalence estimates. Restricting the analysis to only those studies
at a low risk of bias resulted in modestly reduced heterogeneity
and an increased IFR of 0.76% (0.37%–1.15%) (Figure 5).
Other estimates of IFR
Several estimates of IFR were identified but not included in the
meta-analysis as they did not meet the inclusion criteria. The
aggregated best estimate from the Centre for Evidence-Based
exclusion of asymptomatic cases. Using reported estimates of
asymptomatic cases, this estimate would likely match the meta-
analytic IFR; however, this correction could not be applied for the
estimates in this study as it could easily introduce bias in the
results.
Discussion
As pandemic COVID-19 progresses, it is useful to use the IFR
when reporting figures, particularly as some countries begin to
engage in enhanced screening and surveillance, and observe an
increase in positive cases that are asymptomatic and/or mild
enough that they have so far avoided testing (Sutton et al., 2020). It
has been acknowledged that COVID-19 is often spread from
asymptomatic and/or very mildly symptomatic cases – potentially
up to 50% of all patients – and that asymptomatic transmission
Figure 3.Medicine at Oxford University of 0.1%–0.41% (Jason Oke, 2020), and
the pre-print estimate reported by Grewelle and Leo of 1.04%
(0.77%–1.38%) (Grewelle and De Leo, 2020) were both pertinent
but could not be included because of collinearity.
Similarly, the estimate of symptomatic IFR produced by Basu of
1.3% (0.6%–2.1%) (Basu, 2020) was excluded because of the144
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G. Meyerowitz-Katz and L. Merone International Journal of Infectious Diseases 101 (2020) 138–148t is difficult to draw a single conclusion regarding the number.
ggregating the results together provides a point estimate of 0.68%
0.53%–0.82%), but there remains considerable uncertainty about
hether this is a reasonable figure or simply a best guess. It
ppears likely, however, that the true population IFR in most places
rom COVID-19 will lie somewhere between the lower bound and
pper bounds of this estimate.
One reason for the very high heterogeneity is likely that
ifferent countries and regions will experience different death
ates due to the disease. One factor that may impact this is
overnment response, with more prepared countries suffering
ower death rates than those that have sufficient resources to
ombat a large outbreak (Scally et al., 2020). Moreover, it is very
ikely, given the evidence around age-related fatality, that a
ountry with a significantly younger population would see fewer
eaths on average than one with a far older population, given
imilar levels of healthcare provisions between the two. For
Figure 4.
Table 2
Risk of bias in included serosurveys.
Study Overall risk of bias
New York City Moderate
Bendavid et al. High
Streeck et al. Low
Spain Low
Indiana High
Shakiba et al. Moderate
Sweden (Stockholm) Moderate
Stringhini et al. Low
Wu et al. High




Hallal et al. Low
Herzog et al. Moderate
Finland Moderate
ONS England Moderatexample, Israel, with a median age of 30 years, would expect a
ower IFR than Italy, with a much higher median age (45.4 years).
Some included studies (Rinaldi and Paradisi, 2020; Modi et al.,
020a) compared fatality during COVID-19 pandemic with
revious years’ average fatality, determining that mortality has
een higher during the pandemic and whilst correlation does not14
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with those aged over 60 years old experiencing the highest IFR, in5
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most vulnerable in society to illness and likely to carry a higher
disease burden owing to increased susceptibility and comorbidity
(Liu et al., 2020; Rothan and Byrareddy, 2020), the lower IFRs
observed in the younger populations may skew the figure
somewhat. There are some reasonable estimates of fatality in
younger age groups that were not included in the population
estimates (Erikstrup et al., 2020; Valenti et al., 2020; Thompson
et al., 2020), which imply a substantially lower rate of death in the
population below 70 years of age. While these studies were not
considered applicable for quantitative synthesis, they do imply a
lower IFR for those aged 18–70 years. Indeed, a recently published
estimate stratified infection fatality by age and found a very low
risk for under 50 s that increased exponentially with age from
0.0016% <50 years to 0.14% for 50–64 year olds and up to 5.6% for
those 65 years and older (Perez-Saez et al., 2020). This has also
been demonstrated in a pre-print meta-analysis of age-stratified
IFR that found an exponential increase in IFR by age, from 0.005%
for children to 0.2% at age 50, 0.75% at age 60, and 27% for ages 85
cannot be lower than 0.2%, and is likely much higher than this
figure in most scenarios involving overburdened hospitals.
Of note, there appears to be a divergence between estimates
based on serosurveys and those that are modelled or inferred from
other forms of testing, with the IFR based purely on serosurveil-
lance being 0.60% (0.43%–0.77%). Some have argued that serologi-
cal surveys are the only proper way to estimate IFR, which would
lead to the acceptance of this slightly lower IFR as the most likely
estimate (Ioannidis, 2020). However, even these estimates are very
heterogeneous in quality, with some extremely robust data such as
that reported from the Spanish and Swedish health agencies
(Anon, 2020b; Folkhälsomyndigheten, 2020b), and some that have
clear and worrying flaws such as a study from Iran where death
estimates are reportedly substantially lower than the true figure
(Shakiba et al., 2020). However, when taking quality into account,
and only analysing those serosurveys that had a low risk of bias, it
is interesting to note that the inferred IFR rises substantially to
0.76% (0.37%–1.15%). This may be due to the bias in lower-quality
serosurveys being towards a higher prevalence (Sood et al., 2020),
Figure 5.and above (Levin et al., 2020).
While not included in the quantitative synthesis, one paper did
examine the extreme lower bound of IFR of COVID-19 in situations
where the healthcare system has been overwhelmed. This is likely
to be higher than the IFR in a less problematic situation but
demonstrates that the absolute minimum in such a situation146
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Another key issue is accounting for deaths. While official death
counts were used for all serosurvey estimates, and included in all
modelled estimates, these counts are increasingly being recog-
nized as undercounts of the true death figure (Modi et al., 2020a).
Published research is already estimating that, even in manyrsity from ClinicalKey.com.au by Elsevier on April 28, 






























































G. Meyerowitz-Katz and L. Merone International Journal of Infectious Diseases 101 (2020) 138–148ealthy countries with excellent death-reporting systems, more
han 50% of COVID-19 deaths are likely being missed (Modi et al.,
020b; Modig and Ebeling, 2020). It is not unlikely that, after
orrecting for excess mortality not captured in official death-
eporting systems, the IFR of COVID-19 in most populations would
e substantially higher than our analysis suggests. It is also
ossible that the IFR of the disease will drop over time as
reatments improve; however, our analysis at least does not
emonstrate that this has been the case in the first half of 2020.
Conversely, there is evidence that the tests used in these
erosurveys have drawbacks despite their high specificity and
ensitivity. For example, in asymptomatic/mild cases, the tests may
ave reduced sensitivity, leading to a biased overestimation of the
FR (Takahashi et al., 2020). A recent systematic review and meta-
nalysis of serological tests for COVID-19 found that even the
etter serology tests would likely overestimate prevalence in an
rea with few cases and underestimate prevalence when many
eople had already been infected (Lisboa Bastos et al., 2020). In
reas with a prevalence of 1%–2%, for example, the systematic
eview implies that a study employing an enzyme-linked
mmunosorbent assay to examine antibodies would produce an
stimated infection rate almost double the true prevalence. This
ould then cause the IFR to be underestimated by the same
raction.
There are a number of limitations to this research. Importantly,
he heterogeneity in the meta-analysis was very high. This may
ean that the point estimates are less reliable than would be
xpected. It is also notable that any meta-analysis is only as reliable
s the data contained within — this research included a very broad
ange of studies that address slightly different questions with a
ery wide range of methodological rigor, and thus cannot represent
he certainty of any kind. While modelling studies were not
ormally graded, at least one has already been critiqued for simple
athematical errors, and given that many were pre-prints, it is
ard to ascertain if they have provided accurate representations of
he data. Serology studies were at a variable risk of bias, and
nalysing only the highest quality serosurveys produced a higher
stimate than relying on lower quality studies.
Moreover, the quality of included serosurvey estimates was
ften questionable. Many countries have a clear political motiva-
ion to present lower estimates, making it challenging to ascertain
hether these may have biased the reporting of results,
articularly for those places that have only presented results as
ress releases thus far. Some have also been criticized for sampling
ssues that would likely lead to a biased overestimate of population
nfection rates (Bendavid et al., 2020).
Accounting for right-censoring in these estimates was also a
hallenge. Using a 10-day cut-off for deaths is far too crude a
ethod to create a reliable estimate. In some cases, this could be an
verestimate, due to the seroconversion process taking almost as
uch time as the median time until death. Conversely, there is a
ong tail for COVID-19 deaths (Giorgi Rossi et al., 2020), and
herefore it is almost certain that some proportion of the ‘true’
umber of deaths will be missed by using a 10-day cut-off, biasing
he estimated IFRs down. This may be why serosurvey estimates at
rst appear to result in somewhat lower IFRs than modelled and
bservational data suggest.
It is also important to recognize that this is a living estimate.
ith new data being published every single day during this
andemic, in a wide variety of languages and in innumerable
years, the IFR will be revised a number of times. In particular, it is
vital that future research stratifies this estimate by age, as this
appears to be the most significant factor in the risk of death from
COVID-19.
This research has a range of very important implications. Some
countries have announced the aim of pursuing herd immunity
with regard to COVID-19 in the absence of a vaccination. The
aggregated IFR would suggest that, at a minimum, you would
expect 0.45%–0.53% of a population to die before the herd
immunity threshold of the disease (based on R0 of 2.5–3 (Russell
et al., 2020)) was reached (Mahase, 2020). As an example, in the US
this would imply more than 1 million deaths at the lower end of
the scale. Even with a lower herd immunity threshold suggested by
more recent modelling (Aguas et al., 2020), this would imply an
unmanageable number of deaths to reach the threshold across a
country.
This also has implications for future planning. Governments
looking to exit lockdowns should be prepared to see a relatively
high IFR within the population that is infected if COVID-19 re-
emerges. This should inform the decision to relax restrictions,
given that the IFR for people infected with COVID-19 appears to be
not insignificant even in places with very robust healthcare
systems.
Conclusions
Based on a systematic review and meta-analysis of published
evidence on COVID-19 until July 2020, the IFR of the disease
across populations is 0.68% (0.53%–0.82%). However, because of
very high heterogeneity in the meta-analysis, it is difficult to
know if this represents the ‘true’ point estimate. In particular,
higher quality serosurveys with lower risk of bias appeared to
generate higher IFRs. It is likely that, because of age and perhaps
underlying comorbidities in the population, different places will
experience different IFRs due to the disease. Given the issues with
mortality recording, it is also likely that this represents an
underestimate of the true IFR figure. More research looking at
age-stratified IFR is urgently needed to inform policymaking on
this front.
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